Results 1 to 10 of about 22,196 (255)

Bromocriptine improves glucose tolerance in obese mice via central dopamine D2 receptor-independent mechanism. [PDF]

open access: yesPLoS ONE
Bromocriptine, generally regarded as a dopamine D2 receptor agonist, has been used to treat patients with type 2 diabetes in the USA; however, its mechanisms of action including the receptors that mediate its anti-diabetic effects remain unclear ...
Hiroshi Tsuneki   +11 more
doaj   +2 more sources

Atherosclerosis enhances the efficacy of liposome-encapsulated bromocriptine in reducing the incidence of prolactinemia in pituitary tumors [PDF]

open access: yesJournal of Nanobiotechnology
Intranasal drug delivery via nanocarriers has long been a research focus for enhancing drug concentration in the brain. However, the strategy of exploiting blood–brain barrier (BBB) alterations in atherosclerotic mouse models to enhance nanoparticle ...
Zhe Zhang   +12 more
doaj   +2 more sources

Is Abrupt Withdrawal of Benzodiazepines a Risk Factor for Neuroleptic Malignant Syndrome? A Case Report With Single-Dose Haloperidol. [PDF]

open access: yesClin Case Rep
ABSTRACT Neuroleptic malignant syndrome (NMS) is a rare but life‐threatening reaction associated with the use of dopamine‐modulating agents, which presents with symptoms like high fever, muscle rigidity, and autonomic instability. It is known that both the use of dopamine receptor antagonists and the sudden withdrawal of dopamine receptor agonists can ...
Abbasi B, Elyasi F, Aliyali M.
europepmc   +2 more sources

Benzodiazepine and Opioid Withdrawal Induced Neuroleptic Malignant Like Syndrome: A Clinical Case Report With Management Complexities. [PDF]

open access: yesNeuropsychopharmacol Rep
This case report describes a 54‐year‐old man who developed Neuroleptic Malignant‐like Syndrome (NMLS) following the abrupt withdrawal of high‐dose benzodiazepines and opioids. The report highlights the diagnostic challenges in differentiating NMLS from Neuroleptic Malignant Syndrome and emphasizes the critical role of GABAergic dysregulation in its ...
Abbasi B   +3 more
europepmc   +2 more sources

HYPOTHERMIC ACTION OF BROMOCRIPTINE [PDF]

open access: bronzeBritish Journal of Pharmacology, 1975
The body temperature of rats has been studied in a cold environment. In this setting, bromocriptine induced hypothermia. This fall in core temperature was inhibited by pimozide. It was concluded that bromocriptine has a dopamine‐like action in areas of the brain concerned with the control of body temperature, as has previously been shown for ...
D.B. Calne, L.E. Claveria, J.L. Reid
openaire   +5 more sources

Revisiting Late-Onset Bipolar Disorder Associated With Pituitary Adenoma: A Cross-Sectional, Multidisciplinary, Case-Based Analysis. [PDF]

open access: yesBrain Behav
Surveying 300 neurologists, psychiatrists, and family physicians, this study demonstrates discipline‐specific strengths‐imaging (neurology), diagnosis (psychiatry), and pharmacological follow‐up (family medicine)‐yet persistent gaps in holistic care of late‐onset bipolar disorder in elders.
Fidan YS   +6 more
europepmc   +2 more sources

Study on Synergistic Effect of Bromocriptine and Sitagliptin in Streptozotocin-induced Diabetic Rats [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2021
Introduction: Diabetes mellitus is a potentially morbid condition with high prevalence worldwide. Restoration of euglycemia in type 2 diabetes mellitus is difficult to achieve due to its multifactorial pathogenesis and frequently requires multiple ...
Govindaraj Nileshraj   +3 more
doaj   +1 more source

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas

open access: yesBMC Endocrine Disorders, 2021
Background Prolactinoma is a functional pituitary adenoma that secretes excessive prolactin. Dopamine agonists (DAs) such as bromocriptine (BRC) are the first-line treatment for prolactinomas, but the resistance rate is increasing year by year, creating ...
Shuman Wang   +6 more
doaj   +1 more source

Impact of Nano-Bromocriptine on Egg Production Performance and Prolactin Expression in Layers

open access: yesAnimals, 2021
The current study aimed to investigate the potential use of nano-bromocriptine in improving the laying performance of late laying hens by modulating the prolactin gene expression.
Ahmed Dawod   +7 more
doaj   +1 more source

Bromocriptine in Parkinsonism [PDF]

open access: yesBMJ, 1974
Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism who were already receiving conventional therapy, including levodopa.
L. E. Claveria   +5 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy